secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adicet Bio, Inc. (ACET)
CIK:        0001720580
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0000950170-23-019685
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adicet Bio Q1 net loss $30.9M vs prior-year net income; cash $231.6M
--------------------------------------------------------------------

- Net loss of $30.9M ($0.72 loss per share) vs net income of $4.6M in Q1 2022.
- Cash, cash equivalents and investments $231.6M at March 31, expected to fund ops into H1 2025.
- R&D expenses rose to $26.8M from $13.5M YoY, driven by increased CDMO and headcount costs.
- Plan to discuss FDA path for ADI-001 pivotal study in Q2 2023; initiate study in Q4 2023.
- ADI-270 preclinical data at ASGCT May 18; IND for ADI-925 expected H2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720580/000095017023019685/0000950170-23-019685-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720580/000095017023019685/acet-20230509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-019685

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer